Article

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 29.98). 08/2006; 296(1):47-55.
Source: PubMed

ABSTRACT The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation.
To assess efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion SR) and placebo.
Randomized, double-blind, parallel-group, placebo- and active-treatment-controlled, phase 3 clinical trial conducted at 19 US centers from June 19, 2003, to April 22, 2005. Participants were 1025 generally healthy smokers (> or =10 cigarettes/d) with fewer than 3 months of smoking abstinence in the past year, 18 to 75 years old, recruited via advertising.
Participants were randomly assigned in a 1:1:1 ratio to receive brief counseling and varenicline titrated to 1 mg twice per day (n = 352), bupropion SR titrated to 150 mg twice per day (n = 329), or placebo (n = 344) orally for 12 weeks, with 40 weeks of nondrug follow-up.
Primary outcome was the exhaled carbon monoxide-confirmed 4-week rate of continuous abstinence from smoking for weeks 9 through 12. A secondary outcome was the continuous abstinence rate for weeks 9 through 24 and weeks 9 through 52.
For weeks 9 through 12, the 4-week continuous abstinence rates were 44.0% for varenicline vs 17.7% for placebo (odds ratio [OR], 3.85; 95% confidence interval [CI], 2.70-5.50; P<.001) and vs 29.5% for bupropion SR (OR, 1.93; 95% CI, 1.40-2.68; P<.001). Bupropion SR was also significantly more efficacious than placebo (OR, 2.00; 95% CI, 1.38-2.89; P<.001). For weeks 9 through 52, the continuous abstinence rates were 21.9% for varenicline vs 8.4% for placebo (OR, 3.09; 95% CI, 1.95-4.91; P<.001) and vs 16.1% for bupropion SR (OR, 1.46; 95% CI, 0.99-2.17; P = .057). Varenicline reduced craving and withdrawal and, for those who smoked while receiving study drug, smoking satisfaction. No sex differences in efficacy for varenicline were observed. Varenicline was safe and generally well tolerated, with study drug discontinuation rates similar to those for placebo. The most common adverse events for participants receiving active-drug treatment were nausea (98 participants receiving varenicline [28.1%]) and insomnia (72 receiving bupropion SR [21.9%]).
Varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficacious than bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks.
clinicaltrials.gov Identifier: NCT00141206.

0 Bookmarks
 · 
118 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives. The principal objective of this study is to evaluate effectiveness and safety of Varenicline as a smoking cessation treatment in a group of smokers with cardiovascular disease (CVD) in the clinical practice. Material and methods. A review was made of our database and the clinical records that achieved stable CVD (>2 months) were included. This is a descriptive, longitudinal study with retrospective collection of the data. A total of 180 patients, all treated with varenicline, at standard dose of 1 mg every 12 h, for 12 weeks, plus psychological support and self-help material were incorporated. In all, 7 visits (baseline, 2nd and 4th weeks; 2nd, 3rd and 6th month and finally at 52 weeks) were carried out. Telephone calls were also made; the oral manifestation of abstinence was confirmed with measurement of CO in expired air (<10 ppm). Results. Mean age of the participants was 58 years, with predominance of males (78%). Mean age at onset was 15.5 years, mean consumption of cigarettes 25/day. Mean on the Richmond test 8.1 and on the Fagerstrom test 7.5 points. A total of 83% smoked the 1st cigarette in less than half an hour. Abstinence rates at 12 w (52%); at 24 w (44%) and at 52 w (37%). Drop-out rate due to presence of adverse effects was 7.6%. The most frequent undesired effects were, respectively: nauseas, headache, insomnia, vomits and unusual dreams. Conclusions. The participants had an elevated use of cigarettes/day and severe dependence. High motivation, with high score on the Richmond test. Varenicline has proven to be an effective drug treatment to achieve smoking cessation in smokers
    Prevención del Tabaquismo (SEPAR). 11/2014; 16(3):115-120.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 1. Tabaquismo: magnitud del problema El tabaquismo es una enfermedad crónica, adictiva, que evoluciona con recaídas de acuerdo a las definiciones de la Organización Mundial de la Salud (OMS) (1,2) . Es la principal causa de enfermedad y muerte evitables en el mundo y se ha constituido en la mayor pandemia del siglo XX. En lo que respecta al equipo de salud implica asumir roles ineludibles ante esta enfermedad: asistencial, modélico, educativo y social. Es un problema multifacético que repercute en diversos niveles: Individual: como enfermedad crónica que determina una disminución de la calidad y expectativa de vida. Familiar: es fuente de enfermedad en otros integrantes de la familia expuestos al humo de segunda mano (HSM). Es responsable de la perdida de poder adquisitivo en rubros básicos como alimentación y vestimenta por redistribución de los ingresos familiares. Social: es un problema de salud pública que genera alto costo en vidas y en gastos de salud. Produce incremento de los seguros sociales (licencias por enfermedad, jubilaciones precoces) y pérdidas en productividad, pues los fumadores se enferman con mayor frecuencia y tienen ausentismo laboral más prolongado. Económico – comercial: es fuente de movilización de grandes capitales en el mercado lícito e ilícito. Es causa de empobrecimiento de los países porque los ingresos por impuestos cubren sólo un porcentaje de los gastos en salud causados por el consumo de tabaco. Político: requiere para su control un fuerte compromiso político con estrategias nacionales e internacionales. 1.1 Definiciones La OMS fija una serie de condiciones para definir al "Adulto Fumador". En base a las mismas se establece esta clasificación, que es útil a los fines operativos y comparativos entre diferentes encuestas. Se considera: Fumador: la persona que ha fumado por lo menos 1 cigarrillo en los últimos 6 meses. o Fumador diario: la persona que ha fumado por lo menos 1 cigarrillo por día en los últimos 6 meses. o Fumador Ocasional: quién fuma menos de 1 cigarrillo por día. Ex-Fumador: la persona que siendo fumadora se ha mantenido sin fumar por lo menos 6 meses. No fumador: quién nunca ha fumado o fumó menos de 100 cigarrillos en su vida.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Long-term varenicline treatment progressed aortic plaque formation in ApoE KO mice.•Varenicline-aggravated plaque formation was blocked by MLA, an α7 nAChR antagonist.•Varenicline aggravates plaque formation by stimulating α7 nAChR in ApoE KO mice.•Therefore, varenilcine may increase the risk for cardiovascular events.
    Biochemical and Biophysical Research Communications 11/2014; · 2.28 Impact Factor

Full-text (3 Sources)

Download
20 Downloads
Available from
May 28, 2014